Trials / Completed
CompletedNCT05955027
A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Nanjing Zenshine Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of a single oral dose of ZX-7101A on the QTc interval in healthy subjects.
Detailed description
Day 1, Oral fasting administration of ZX-7101A tablets 80mg, 160mg and placebo, 6 visit periods were set from days 2 to 15(Day2, Day3, Day5, Day7, Day10, Day15)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZX-7101A | a drug to treat influenza, oral |
| DRUG | Placebo | placebo control, oral |
Timeline
- Start date
- 2023-07-08
- Primary completion
- 2023-08-05
- Completion
- 2023-12-15
- First posted
- 2023-07-20
- Last updated
- 2024-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05955027. Inclusion in this directory is not an endorsement.